Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment: 2022-2024

Historic Asset Writedowns and Impairment for BridgeBio Pharma (BBIO) over the last 2 years, with Dec 2024 value amounting to $271,000.

  • BridgeBio Pharma's Asset Writedowns and Impairment was N/A to $67,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $12.7 million, marking a year-over-year change of. This contributed to the annual value of $271,000 for FY2024, which is N/A change from last year.
  • Per BridgeBio Pharma's latest filing, its Asset Writedowns and Impairment stood at $271,000 for FY2024, which was down 97.87% from $12.7 million recorded in FY2022.
  • BridgeBio Pharma's Asset Writedowns and Impairment's 5-year high stood at $12.7 million during FY2022, with a 5-year trough of $271,000 in FY2024.
  • Moreover, its 2-year median value for Asset Writedowns and Impairment was $6.5 million (2022), whereas its average is $6.5 million.